The molecule index

This index records, for each peptide, what United States law currently permits: whether an FDA-approved product exists, whether a licensed 503A pharmacy may compound it, or whether no lawful route exists at all. Every status on this page was last verified in August 2026, because the ground moved twice in 2026 and a statement about peptide law without a date is not a statement.

FDA-approvedCompoundable (503A)PCAC-recommended · pendingNo lawful routeNomination withdrawn

Molecule	Class	US status	Position
TesamorelinEGRIFTA; GHRH(1–44) analogue	GH secretagogues	FDA-approved	Approved since 2010; EGRIFTA WR (weekly reconstitution) approved March 2025.
BPC-157Body Protection Compound 157; pentadecapeptide BPC	Repair peptides	PCAC-recommended · pending	Removed from Category 2 in April 2026; PCAC voted 8–6 to recommend 503A listing in July 2026; no FDA final rule.
SemaglutideOzempic; Wegovy; Rybelsus	GLP-1 receptor agonists	FDA-approved	Approved brand products; mass compounding ended after the shortage resolved; narrow patient-specific 503A path remains.
TirzepatideMounjaro; Zepbound	GLP-1 receptor agonists	FDA-approved	Approved brand products; shortage resolved October 2024; same narrow 503A posture as semaglutide.
SermorelinGHRH(1–29); formerly Geref	GH secretagogues	Compoundable (503A)	Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A.
NAD+Nicotinamide adenine dinucleotide	Mitochondrial	Compoundable (503A)	Category 1 of the interim 503A bulks list; compoundable with a valid prescription while FDA evaluates.
Glutathione	Mitochondrial	Compoundable (503A)	Category 1 of the interim 503A bulks list; compoundable with a valid prescription.
CJC-1295	GH secretagogues	Nomination withdrawn	Removed from Category 2 in September 2024 after its nominators withdrew; on no list; no lawful compounding route.
Ipamorelin	GH secretagogues	Nomination withdrawn	Nomination withdrawn September 2024; on no list; no lawful compounding route.
GHK-CuCopper tripeptide-1	Repair peptides	No lawful route	Injectable form removed from Category 2 in April 2026 but not reviewed at the July PCAC meeting; topical cosmetic use is a separate question.
MOTS-c	Mitochondrial	PCAC-recommended · pending	Removed from Category 2 in April 2026; PCAC voted 7–5 to recommend 503A listing in July 2026; no FDA final rule.
TB-500Thymosin beta-4 fragment	Repair peptides	PCAC-recommended · pending	Removed from Category 2 in April 2026; PCAC voted 8–6 to recommend 503A listing in July 2026; no FDA final rule.
KPVLysine-proline-valine; alpha-MSH fragment	Repair peptides	PCAC-recommended · pending	Removed from Category 2 in April 2026; PCAC voted 8–6 to recommend 503A listing in July 2026; no FDA final rule.
Semax	Neuropeptides	PCAC-recommended · pending	Removed from Category 2 in April 2026; PCAC voted 8–5 to recommend 503A listing in July 2026; no FDA final rule.
EpitalonEpithalon; AEDG tetrapeptide	Longevity peptides	PCAC-recommended · pending	Removed from Category 2 in April 2026; PCAC voted 7–5 to recommend 503A listing in July 2026; no FDA final rule.
DSIPDelta sleep-inducing peptide; emideltide	Neuropeptides	No lawful route	Removed from Category 2 in April 2026; the only peptide PCAC voted AGAINST (6–7) at the July 2026 meeting; no lawful route.

TesamorelinFDA-approved
EGRIFTA; GHRH(1–44) analogue
Approved since 2010; EGRIFTA WR (weekly reconstitution) approved March 2025.
BPC-157PCAC-recommended · pending
Body Protection Compound 157; pentadecapeptide BPC
Removed from Category 2 in April 2026; PCAC voted 8–6 to recommend 503A listing in July 2026; no FDA final rule.
SemaglutideFDA-approved
Ozempic; Wegovy; Rybelsus
Approved brand products; mass compounding ended after the shortage resolved; narrow patient-specific 503A path remains.
TirzepatideFDA-approved
Mounjaro; Zepbound
Approved brand products; shortage resolved October 2024; same narrow 503A posture as semaglutide.
SermorelinCompoundable (503A)
GHRH(1–29); formerly Geref
Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A.
NAD+Compoundable (503A)
Nicotinamide adenine dinucleotide
Category 1 of the interim 503A bulks list; compoundable with a valid prescription while FDA evaluates.
GlutathioneCompoundable (503A)
Category 1 of the interim 503A bulks list; compoundable with a valid prescription.
CJC-1295Nomination withdrawn
Removed from Category 2 in September 2024 after its nominators withdrew; on no list; no lawful compounding route.
IpamorelinNomination withdrawn
Nomination withdrawn September 2024; on no list; no lawful compounding route.
GHK-CuNo lawful route
Copper tripeptide-1
Injectable form removed from Category 2 in April 2026 but not reviewed at the July PCAC meeting; topical cosmetic use is a separate question.
MOTS-cPCAC-recommended · pending
Removed from Category 2 in April 2026; PCAC voted 7–5 to recommend 503A listing in July 2026; no FDA final rule.
TB-500PCAC-recommended · pending
Thymosin beta-4 fragment
Removed from Category 2 in April 2026; PCAC voted 8–6 to recommend 503A listing in July 2026; no FDA final rule.
KPVPCAC-recommended · pending
Lysine-proline-valine; alpha-MSH fragment
Removed from Category 2 in April 2026; PCAC voted 8–6 to recommend 503A listing in July 2026; no FDA final rule.
SemaxPCAC-recommended · pending
Removed from Category 2 in April 2026; PCAC voted 8–5 to recommend 503A listing in July 2026; no FDA final rule.
EpitalonPCAC-recommended · pending
Epithalon; AEDG tetrapeptide
Removed from Category 2 in April 2026; PCAC voted 7–5 to recommend 503A listing in July 2026; no FDA final rule.
DSIPNo lawful route
Delta sleep-inducing peptide; emideltide
Removed from Category 2 in April 2026; the only peptide PCAC voted AGAINST (6–7) at the July 2026 meeting; no lawful route.

The record in motion

July 2026: The Pharmacy Compounding Advisory Committee recommended six peptides for the 503A list, including BPC-157 by an 8–6 vote; the votes are advisory, and FDA rulemaking is still required. A further PCAC meeting is announced for early 2027.
April 2026: FDA removed twelve peptides from Category 2 of the interim 503A bulks list without adding them to Category 1; the removal ended explicit prohibitions but authorized nothing.